Background: Hypertension is the leading modifiable risk factor for premature death globally despite the existence of evidence-based and cost-effective treatments. Medication nonadherence is cited as the main cause of treatment failure for hypertension. In Peru, adherence to anti-hypertensive medications of individuals with both hypertension and type 2 diabetes (T2D) is not well studied. The few studies that have investigated differences in anti-hypertensive medication adherence among patients with and without T2D have demonstrated both positive and negative effects. Methods: In a cross-sectional study in Puno, Peru, we compared anti-hypertensive medication adherence in individuals with hypertension between those with and without comorbid T2D. The primary outcome was adherence to anti-hypertensive medications as assessed by the Hill-Bone Compliance scale. The primary exposure variable was comorbidity status (i.e., having hypertension and diabetes vs. hypertension alone). Results: Of the 204 participants with hypertension (mean age 67 ± 11 years, 60% female), 42 (21%) had comorbid diabetes. Participants with comorbid disease had higher overall anti-hypertensive adherence scores (49.5 ± 2.8 vs. 48.0 ± 4.1 points; p<0.001) and higher medication adherence scores (32.8 ± 2.2 vs. 31.3 ± 3.7 points; p<0.01) when compared to those with hypertension alone. In multivariable regression, comorbid diabetes and monthly income above 250 soles (68 USD) were associated with higher Hill-Bone Compliance scale scores by 1.5 ± 0.7 points (p=0.025) and 2.0 ± 0.7 points (p<0.01), respectively. Conclusions: Participants with comorbid hypertension and diabetes exhibited higher adherence to anti-hypertensive medications when compared to those with hypertension alone, suggesting that individuals with comorbid disease are more likely to adhere to anti-hypertensive medications.
14 September 2022 in Journal of Pediatric Intensive Care
The diagnosis and management of central diabetes insipidus in critically ill children is not standardized. Our objective was to characterize differences between Pediatric Critical Care Medicine (PCCM) and Pediatric Endocrinology (PE) clinicians in the diagnosis and management of new-onset CDI in the pediatric intensive care unit. We also sought to characterize knowledge gaps among general pediatrics (GP) residents. This is a scenario-based survey to assess patterns of diagnosis and management of new-onset CDI that was distributed to PCCM, PE, and GP clinicians who work in a quaternary care urban children's hospital. Of 275 PCCM, PE, and GP clinicians surveyed, 158 (57%) responded. More PCCM than PE clinicians relied on serum sodium levels (96 vs. 75%, p <0.01) and more PE than PCCM clinicians relied on serum osmolality (91 vs. 40%, p < .001) for diagnosis. Fewer PCCM than PE clinicians favored restricting IV fluids to two-thirds maintenance rate (4 vs. 37%, p <0.001). More PCCM than PE clinicians favored a starting dose of 0.5 milli-units/kg/h for IV vasopressin infusion (76 vs. 53%, p = 0.048). More PCCM clinicians than PE clinicians favored titrating the IV vasopressin infusion every 20 minutes (24 vs. 2%, p = 0.02), whereas more PE clinicians than PCCM clinicians favored titration every 60 minutes (38 vs. 14%, p = 0.03). GP residents earlier in training had greater self-reported gaps in knowledge. We observed substantial variability in the diagnosis and management of new-onset CDI in critically ill children among PCCM, PE, and GP clinicians. There is a need for greater standardization in care of these patients.